hyperphosphataemia love

hyperphosphataemia

Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun Alternative form of hyperphosphatemia.

Etymologies

Sorry, no etymologies found.

Examples

  • Renvelais also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    undefined

  • The benefits with Renvelaare its phosphate-lowering effect for controlling hyperphosphataemia in adult patients on dialysis and in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    undefined

  • Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    undefined

  • (CHMP) adopted a positive opinion, ** recommending to grant a marketing authorisation for the medicinal product Renvela, 800mg film-coated tablets and 1.6 and 2.4 g powder for oral suspension, intended for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

    undefined

  • Notes to Editors ABOUT FOSRENOL (R) (lanthanum carbonate) FOSRENOL is indicated: - In the EU as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis.

    undefined

  • - FOSRENOL (R) (lanthanum carbonate) Now Approved in the EU to Treat hyperphosphataemia

    undefined

  • * Renvela (sevelamer carbonate), from people) Europe B.V., indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, and for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus >

    Forbes.com: News

  • The approved indication is: "Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

    undefined

  • SHPGY), the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL (R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1. 78mmol/L (5. 5mg/dL).

    undefined

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.